---
title: Why the Life Science Industry Should Care About the Proposed HTI-2 Rule
description: The proposed HTI-2 rule is a critical piece of improving data fluidity, this blog highlights why life sciences companies should monitor this rule and consider engaging by submitting comments.
image: https://blog.pocp.com/hubfs/_HTI2%20Life%20Sciences.png
---
[](https://www.pocp.com/)
# Accelerating client's success
# using Health IT and
# business process solutions...
[Learn More](https://www.pocp.com/the-pocp-story/)
# Simplifying
# regulatory
## compliance...
[Learn More](https://www.pocp.com/regulatory-resource-center/)
# Creating value in today's
# healthcare ecosystem...
[Learn More](https://www.pocp.com/our-client/)
- Consulting
- [Strategy & Market Intelligence](https://www.pocp.com/strategy-market-intelligence/)
- [Education & Research](https://www.pocp.com/education-research/)
- [Value-Based Care Interoperability Roadmap](https://info.pocp.com/en-us/value-based-care-interoperability-strategy-and-roadmap)
- [Multi-stakeholder Collaboratives, Program Design and Management](https://www.pocp.com/multi-stakeholder-initiatives_program-design_management)
- [EHR Training Programs](https://www.pocp.com/ehr-training-programs/)
- [Life Sciences](https://www.pocp.com/life-sciences)
- [Regulatory Resource Center](https://www.pocp.com/regulatory-resource-center)
- About Us
- [The POCP Story](https://www.pocp.com/the-pocp-story/)
- [Our Clients](https://www.pocp.com/our-client/)
- [Health & IT Vendors](https://www.pocp.com/our-client/health-it-vendors/)
- [Payers & PBMS](https://www.pocp.com/our-client/payers-pbms/)
- [Accountable Care](https://www.pocp.com/our-client/accountable-care/)
- [Health Information Exchange](https://www.pocp.com/resource-library/health-information-exchange/)
- [Our Team](https://www.pocp.com/our-team/)
- [Government Contracting](https://info.pocp.com/gsa)
- [Press](https://www.pocp.com/press/)
- [Calendar](https://info.pocp.com/en-us/events)
- [Careers at POCP](https://www.pocp.com/the-pocp-story/careers-at-pocp/)
- Insights
- [Articles and Industry Comments](https://www.pocp.com/articles/)
- [Blog](https://blog.pocp.com/blog/)
- [Newsletters HIT Perspectives](https://www.pocp.com/insight/newsletters-2/)
- [Newsletters Biopharma](https://www.pocp.com/newsletters-biopharma/)
- [POCP Industry Reports](https://www.pocp.com/industry-reports)
- [POCP Industry Reports](https://www.pocp.com/industry-reports)
- [ePrior Authorization’s Real Benefits: Reducing Frictional Costs and Speeding Time to Therapy](https://www.pocp.com/downloads/ePAReport)
- [Real-Time Pharmacy Benefit Check Report](https://www.pocp.com/pocp-industry-reports/real-time-pharmacy-benefit-check-report/)
- [Fighting the Opioid Epidemic at the State- and Rx-Level Report](https://www.pocp.com/downloads/fighting-opioid-epidemic-at-rx-level-report)
- [ePrescribing State Law On-Demand](https://www.pocp.com/downloads/eprescribing-state-law-on-demand/)
- [State Law Review](https://www.pocp.com/statelawreview/)
- [Navigator](https://www.pocp.com/navigator/)
- [Podcasts](https://info.pocp.com/en-us/the-dish-on-health-it-podcast)
- [Presentations and Webinars](https://www.pocp.com/presentations/)
- [Resource Library](https://www.pocp.com/resource-library/)
- [White Papers, Webinars and Case Studies](https://www.pocp.com/white-papers-webinars-and-case-studies-2/)
- [Our video channel](https://www.pocp.com/our-video-channel)
- [Contact](https://www.pocp.com/contact/)
- Consulting
- [Strategy & Market Intelligence](https://www.pocp.com/strategy-market-intelligence/)
- [Education & Research](https://www.pocp.com/education-research/)
- [Value-Based Care Interoperability Roadmap](https://info.pocp.com/en-us/value-based-care-interoperability-strategy-and-roadmap)
- [Multi-stakeholder Collaboratives, Program Design and Management](https://www.pocp.com/multi-stakeholder-initiatives_program-design_management)
- [EHR Training Programs](https://www.pocp.com/ehr-training-programs/)
- [Life Sciences](https://www.pocp.com/life-sciences)
- [Regulatory Resource Center](https://www.pocp.com/regulatory-resource-center)
- About Us
- [The POCP Story](https://www.pocp.com/the-pocp-story/)
- [Our Clients](https://www.pocp.com/our-client/)
- [Health & IT Vendors](https://www.pocp.com/our-client/health-it-vendors/)
- [Payers & PBMS](https://www.pocp.com/our-client/payers-pbms/)
- [Accountable Care](https://www.pocp.com/our-client/accountable-care/)
- [Health Information Exchange](https://www.pocp.com/resource-library/health-information-exchange/)
- [Our Team](https://www.pocp.com/our-team/)
- [Government Contracting](https://info.pocp.com/gsa)
- [Press](https://www.pocp.com/press/)
- [Calendar](https://info.pocp.com/en-us/events)
- [Careers at POCP](https://www.pocp.com/the-pocp-story/careers-at-pocp/)
- Insights
- [Articles and Industry Comments](https://www.pocp.com/articles/)
- [Blog](https://blog.pocp.com/blog/)
- [Newsletters HIT Perspectives](https://www.pocp.com/insight/newsletters-2/)
- [Newsletters Biopharma](https://www.pocp.com/newsletters-biopharma/)
- [POCP Industry Reports](https://www.pocp.com/industry-reports)
- [POCP Industry Reports](https://www.pocp.com/industry-reports)
- [ePrior Authorization’s Real Benefits: Reducing Frictional Costs and Speeding Time to Therapy](https://www.pocp.com/downloads/ePAReport)
- [Real-Time Pharmacy Benefit Check Report](https://www.pocp.com/pocp-industry-reports/real-time-pharmacy-benefit-check-report/)
- [Fighting the Opioid Epidemic at the State- and Rx-Level Report](https://www.pocp.com/downloads/fighting-opioid-epidemic-at-rx-level-report)
- [ePrescribing State Law On-Demand](https://www.pocp.com/downloads/eprescribing-state-law-on-demand/)
- [State Law Review](https://www.pocp.com/statelawreview/)
- [Navigator](https://www.pocp.com/navigator/)
- [Podcasts](https://info.pocp.com/en-us/the-dish-on-health-it-podcast)
- [Presentations and Webinars](https://www.pocp.com/presentations/)
- [Resource Library](https://www.pocp.com/resource-library/)
- [White Papers, Webinars and Case Studies](https://www.pocp.com/white-papers-webinars-and-case-studies-2/)
- [Our video channel](https://www.pocp.com/our-video-channel)
- [Contact](https://www.pocp.com/contact/)
# Insights: Brief Points of View
# POCP Blog
---
## Why the Life Science Industry Should Care About the Proposed HTI-2 Rule
- August 22, 2024
- By [Kim Boyd](https://blog.pocp.com/blog/author/kim-boyd)
- [0 Comment](https://blog.pocp.com/blog/why-the-life-science-industry-should-care-about-the-proposed-hti-2-rule#comments-listing)
Share this story:
In an era where data fluidity is transforming healthcare, life sciences manufacturers must stay attuned to evolving Health IT policies given that many of these policies have downstream effects on life sciences and access to expanded deidentified and aggregated datasets. The proposed HTI-2 rule is a critical piece of this transformation, offering profound implications for the industry. Here’s why life sciences companies should monitor this rule and consider engaging by submitting comments (Due October 4, 2024).
### Real-Time Prescription Benefit (RTPB) Certification: A Market Access Opportunity
The HTI-2 rule proposes the certification of Real-Time Prescription Benefit (RTPB) standards, which is a game-changer for patients' access to their needed therapies. By standardizing and certifying RTPB solutions, the rule aims to make coverage and cost-related information more readily accessible and standardize the way the information is accessed and delivered, reducing data fragmentation. Should this rule be finalized the way it is proposed, certification requirements would be effective January 1, 2028. This increased transparency will:
- **Improve Access**: Patients and providers will have real-time information on drug coverage, costs, and alternatives, facilitating more informed and timely treatment decisions.
- **Enhance Market Reach**: Pharmaceutical companies can benefit from improved communications and clear approval requirements between payers and providers.
### Richer Data Sharing for Prior Authorization (PA) Insights
The proposed rule emphasizes enhanced prior authorization (PA) processes through better data sharing. This can provide life sciences manufacturers with valuable insights into patient and drug mix, as well as denial statistics:
- **Understanding Barriers**: Detailed data on PA denials can help manufacturers identify patterns and barriers, such as the lack of real-world efficacy data, leading to targeted improvements.
- **Creating New Clinical Guidelines**: Armed with comprehensive data, manufacturers can work with healthcare providers to develop new clinical guidelines that improve patient outcomes and reduce denials.
### Rethinking Digital Health Offerings
The HTI-2 rule emphasizes the importance of capturing and utilizing health data effectively which may encourage a reevaluation of digital health offerings:
- **Patient Education**: Enhanced data sharing enables better patient education programs, ensuring patients understand their treatments and adhere to prescribed regimens.
- **Early Testing and Identification**: Identifying patients early for testing and treatments becomes more streamlined, improving overall health outcomes and pharmaceutical companies will benefit from faster diagnoses and treatment of patients.
- **Data from Digital Health Programs**: Integrating data from digital health initiatives provides a richer dataset for manufacturers to analyze and improve their products. Collaborating with platforms like CoverMyMeds can yield deeper insights into reasons for PA denials and improve product efficacy.
### Bulk Data Access: A Treasure Trove for Analytics
The rule’s provision for bulk data access using HL7 FHIR Bulk Data Access v2.0.0 may improve life sciences manufacturers access to:
- **Enhanced Analytics**: Given various deidentified data access relationships, access to bulk data could provide greater opportunities for the performance of comprehensive data analyses, leading to better population health management and targeted interventions.
- **Larger datasets**: Access to large datasets can drive more robust clinical research and innovation, accelerating the development of new treatments.
### Immunization Registry Reporting
New standards for immunization registry reporting under HTI-2 will ensure better tracking and management of vaccine data:
- **Enhanced Data Insights:** Improved standards for immunization registry reporting by healthcare providers could lead to more comprehensive and accurate vaccine uptake data. This could provide valuable insights for manufacturers in areas such as:
- Market penetration analysis
- Identifying areas of low vaccination rates for targeted education campaigns
- Post-market surveillance and real-world evidence studies
- **Public Health Collaboration:** While not directly reporting to registries, manufacturers could potentially leverage the improved data standards to enhance collaboration with public health authorities on vaccine effectiveness studies or outbreak response planning.
- **Supply Chain Optimization:** Better immunization tracking could lead to more accurate demand forecasting, helping manufacturers optimize their production and distribution strategies. The Broader Implications for Health IT Policy
Beyond the specifics of HTI-2, life sciences manufacturers should recognize the broader implications of evolving Health IT policies:
- **Foundational Business Impacts**: Data fluidity facilitated by policies like HTI-2 may improve foundational business processes, from R&D to market access and patient engagement.
- **Enhanced Collaboration**: Improved data exchange standards promote collaboration across the healthcare ecosystem, leading to more cohesive and effective patient care strategies that will benefit life sciences brands.
The proposed HTI-2 rule represents a significant step forward in health IT policy, with down-stream implications for life sciences manufacturers. By engaging with these developments, companies can ensure they are at the forefront of a more transparent, efficient, and patient-centric healthcare landscape. Monitoring and adapting to these changes will not only enhance market access but also drive innovation and improve patient outcomes. Life sciences companies must stay informed and proactive in responding to these critical regulatory shifts.
### How POCP Can Help
Navigating the complexities of HTI-2 and other health IT policies can be challenging. Point-of-Care Partners (POCP) is here to help your organization monitor, understand, react to and plan for these industry changes. Our team of experts has deep knowledge of health IT policy and how to make strategic adjustments. Set up a time to chat by reaching out to Kim Boyd at kim.boyd@pocp.com.
For more details, refer to the [ONC HTI-2 Proposed Rule](https://www.healthit.gov/sites/default/files/page/2024-07/ONC_HTI-2_Proposed_Rule.pdf) and the [HHS Press Release](https://www.hhs.gov/about/news/2024/07/10/hhs-proposes-hti-2-rule-improve-patient-engagement-information-sharing-public-health-interoperability.html).
- Post Categories
- [Real-Time Pharmacy Benefit Check](https://blog.pocp.com/blog/tag/real-time-pharmacy-benefit-check)
- [Life Sciences](https://blog.pocp.com/blog/tag/life-sciences)
- [Policy](https://blog.pocp.com/blog/tag/policy)
- [Prior Authorization](https://blog.pocp.com/blog/tag/prior-authorization)
- [Health IT Policy](https://blog.pocp.com/blog/tag/health-it-policy)
- [HTI-2](https://blog.pocp.com/blog/tag/hti-2)
- [RTPB](https://blog.pocp.com/blog/tag/rtpb)
# POCP Blog
---
Search
- There are no suggestions because the search field is empty.
### RECENT POSTS
### CATEGORIES
- [Interoperability (39)](https://blog.pocp.com/blog/tag/interoperability)
- [Health IT Policy (38)](https://blog.pocp.com/blog/tag/health-it-policy)
- [CMS (28)](https://blog.pocp.com/blog/tag/cms)
- [EHR (24)](https://blog.pocp.com/blog/tag/ehr)
- [FHIR (24)](https://blog.pocp.com/blog/tag/fhir)
- [Health IT Trends (20)](https://blog.pocp.com/blog/tag/health-it-trends)
- [ePrescribing (19)](https://blog.pocp.com/blog/tag/eprescribing)
- [Prior Authorization (16)](https://blog.pocp.com/blog/tag/prior-authorization)
- [Real-Time Benefit Check (15)](https://blog.pocp.com/blog/tag/real-time-benefit-check)
- [Real-Time Pharmacy Benefit Check (15)](https://blog.pocp.com/blog/tag/real-time-pharmacy-benefit-check)
- [Regulatory Trends (15)](https://blog.pocp.com/blog/tag/regulatory-trends)
- [APIs (13)](https://blog.pocp.com/blog/tag/apis)
- [Artificial Intelligence (12)](https://blog.pocp.com/blog/tag/artificial-intelligence)
- [electronic prior authorization (12)](https://blog.pocp.com/blog/tag/electronic-prior-authorization)
- [health IT (12)](https://blog.pocp.com/blog/tag/health-it)
- [Life Sciences (10)](https://blog.pocp.com/blog/tag/life-sciences)
- [NCPDP (10)](https://blog.pocp.com/blog/tag/ncpdp)
- [Policy (10)](https://blog.pocp.com/blog/tag/policy)
- [electronic health records (9)](https://blog.pocp.com/blog/tag/electronic-health-records)
- [pharmacy interoperability (9)](https://blog.pocp.com/blog/tag/pharmacy-interoperability)
- [ASTP (8)](https://blog.pocp.com/blog/tag/astp)
- [CMS NPRM (8)](https://blog.pocp.com/blog/tag/cms-nprm)
- [health information exchange (8)](https://blog.pocp.com/blog/tag/health-information-exchange)
- [HL7 (7)](https://blog.pocp.com/blog/tag/hl7)
- [Payer (7)](https://blog.pocp.com/blog/tag/payer)
- [Specialty Pharmacy (7)](https://blog.pocp.com/blog/tag/specialty-pharmacy)
- [Standards Development (7)](https://blog.pocp.com/blog/tag/standards-development)
- [TEFCA (7)](https://blog.pocp.com/blog/tag/tefca)
- [Value-Based Care (7)](https://blog.pocp.com/blog/tag/value-based-care)
- [e-Prescribing (7)](https://blog.pocp.com/blog/tag/e-prescribing)
- [electronic prescribing (7)](https://blog.pocp.com/blog/tag/electronic-prescribing)
- [Da Vinci Project (6)](https://blog.pocp.com/blog/tag/da-vinci-project)
- [HTI-2 (6)](https://blog.pocp.com/blog/tag/hti-2)
- [ONC (6)](https://blog.pocp.com/blog/tag/onc)
- [Strategy and Research (6)](https://blog.pocp.com/blog/tag/strategy-and-research)
- [healthcare reform (6)](https://blog.pocp.com/blog/tag/healthcare-reform)
- [21st Century Cures Act (5)](https://blog.pocp.com/blog/tag/21st-century-cures-act)
- [Consent (5)](https://blog.pocp.com/blog/tag/consent)
- [EPCS (5)](https://blog.pocp.com/blog/tag/epcs)
- [Federal Healthcare Policy (5)](https://blog.pocp.com/blog/tag/federal-healthcare-policy)
- [HHS (5)](https://blog.pocp.com/blog/tag/hhs)
- [Information Blocking (5)](https://blog.pocp.com/blog/tag/information-blocking)
- [NCPDP SCRIPT (5)](https://blog.pocp.com/blog/tag/ncpdp-script)
- [Patient Data (5)](https://blog.pocp.com/blog/tag/patient-data)
- [Payer Interoperability (5)](https://blog.pocp.com/blog/tag/payer-interoperability)
- [Pharmacy (5)](https://blog.pocp.com/blog/tag/pharmacy)
- [health equity (5)](https://blog.pocp.com/blog/tag/health-equity)
- [pharmaceutical marketing (5)](https://blog.pocp.com/blog/tag/pharmaceutical-marketing)
- [population health (5)](https://blog.pocp.com/blog/tag/population-health)
- [Clinical Decision Support (4)](https://blog.pocp.com/blog/tag/cds)
- [Digital Health Programs (4)](https://blog.pocp.com/blog/tag/digital-health-programs)
- [Digital Therapeutics (4)](https://blog.pocp.com/blog/tag/digital-therapeutics)
- [EHR Dashboard (4)](https://blog.pocp.com/blog/tag/ehr-dashboard)
- [EHR Usability (4)](https://blog.pocp.com/blog/tag/ehr-usability)
- [HIE (4)](https://blog.pocp.com/blog/tag/hie)
- [Health Plans (4)](https://blog.pocp.com/blog/tag/health-plans)
- [Health Technology Solutions (4)](https://blog.pocp.com/blog/tag/health-technology-solutions)
- [Meaningful Use (4)](https://blog.pocp.com/blog/tag/meaningful-use)
- [PDMP (4)](https://blog.pocp.com/blog/tag/pdmp)
- [Pharmacy Benefit Management (4)](https://blog.pocp.com/blog/tag/pharmacy-benefit-management)
- [Strategic roadmap (4)](https://blog.pocp.com/blog/tag/strategic-roadmap)
- [burden reduction (4)](https://blog.pocp.com/blog/tag/burden-reduction)
- [ePrior Authorization (4)](https://blog.pocp.com/blog/tag/eprior-authorization)
- [healthcare regulations (4)](https://blog.pocp.com/blog/tag/healthcare-regulations)
- [pharmacy advance practice (4)](https://blog.pocp.com/blog/tag/pharmacy-advance-practice)
- [price transparency (4)](https://blog.pocp.com/blog/tag/price-transparency)
- [COVID-19 (3)](https://blog.pocp.com/blog/tag/covid-19)
- [Clinical Calculators (3)](https://blog.pocp.com/blog/tag/clinical-calculators)
- [Data Governance (3)](https://blog.pocp.com/blog/tag/data-governance)
- [Diabetes Care (3)](https://blog.pocp.com/blog/tag/diabetes-care)
- [Digital Health (3)](https://blog.pocp.com/blog/tag/digital-health)
- [Drug price transparency (3)](https://blog.pocp.com/blog/tag/drug-price-transparency)
- [EHR Reports (3)](https://blog.pocp.com/blog/tag/ehr-reports)
- [HIMSS (3)](https://blog.pocp.com/blog/tag/himss)
- [Healthcare AI (3)](https://blog.pocp.com/blog/tag/healthcare-ai)
- [Implementation (3)](https://blog.pocp.com/blog/tag/implementation)
- [Innovation (3)](https://blog.pocp.com/blog/tag/innovation)
- [Medication Therapy Management (3)](https://blog.pocp.com/blog/tag/mtm)
- [National Patient Identifier (3)](https://blog.pocp.com/blog/tag/national-patient-identifier)
- [Patient Safety (3)](https://blog.pocp.com/blog/tag/patient-safety)
- [Pharmacy Benefit (3)](https://blog.pocp.com/blog/tag/pharmacy-benefit)
- [Request for Information (3)](https://blog.pocp.com/blog/tag/request-for-information)
- [Speed to Therapy (3)](https://blog.pocp.com/blog/tag/speed-to-therapy)
- [state prescribing laws (3)](https://blog.pocp.com/blog/tag/state-prescribing-laws)
- [Administrative Burden (2)](https://blog.pocp.com/blog/tag/administrative-burden)
- [CDC (2)](https://blog.pocp.com/blog/tag/cdc)
- [Centers for Disease Control (2)](https://blog.pocp.com/blog/tag/centers-for-disease-control)
- [Controlled Substances (2)](https://blog.pocp.com/blog/tag/controlled-substances)
- [Data Efficiency (2)](https://blog.pocp.com/blog/tag/data-efficiency)
- [EHR Certification (2)](https://blog.pocp.com/blog/tag/ehr-certification)
- [EHR Guides (2)](https://blog.pocp.com/blog/tag/ehr-guides)
- [EHRs (2)](https://blog.pocp.com/blog/tag/ehrs)
- [Epic (2)](https://blog.pocp.com/blog/tag/epic)
- [Formulary and Benefit (2)](https://blog.pocp.com/blog/tag/formulary-and-benefit)
- [H.R. 6 (2)](https://blog.pocp.com/blog/tag/h-r-6)
- [Market Assessment (2)](https://blog.pocp.com/blog/tag/market-assessment)
- [Medical Benefit (2)](https://blog.pocp.com/blog/tag/medical-benefit)
- [Medical Pharmacy Benefit Integration (2)](https://blog.pocp.com/blog/tag/medical-pharmacy-benefit-integration)
- [Medicare Payment Reform (2)](https://blog.pocp.com/blog/tag/medicare-payment-reform)
- [Medication Adherence (2)](https://blog.pocp.com/blog/tag/medication-adherence)
- [Member Data (2)](https://blog.pocp.com/blog/tag/member-data)
- [NCPDP Telecommunications Standard Version F6 (2)](https://blog.pocp.com/blog/tag/ncpdp-telecommunications-standard-version-f6)
- [ONC Physician Burden Reduction (2)](https://blog.pocp.com/blog/tag/onc-physician-burden-reduction)
- [Opioid prescribing laws (2)](https://blog.pocp.com/blog/tag/opioid-prescribing-laws)
- [PGx (2)](https://blog.pocp.com/blog/tag/pgx)
- [Part D (2)](https://blog.pocp.com/blog/tag/part-d)
- [Patient Record Sharing (2)](https://blog.pocp.com/blog/tag/patient-record-sharing)
- [Pharmaceutical Manufacturers (2)](https://blog.pocp.com/blog/tag/pharmaceutical-manufacturers)
- [Policy monitoring (2)](https://blog.pocp.com/blog/tag/policy-monitoring)
- [Pre-approval Information Exchange (2)](https://blog.pocp.com/blog/tag/pre-approval-information-exchange)
- [Precision Medicine (2)](https://blog.pocp.com/blog/tag/precision-medicine)
- [REMS (2)](https://blog.pocp.com/blog/tag/rems)
- [Regulatory landscape (2)](https://blog.pocp.com/blog/tag/regulatory-landscape)
- [Specialty Pharmacy Automation (2)](https://blog.pocp.com/blog/tag/specialty-pharmacy-automation)
- [Specialty ePrescribing (2)](https://blog.pocp.com/blog/tag/specialty-eprescribing)
- [Speed to Medication Therapy (2)](https://blog.pocp.com/blog/tag/speed-to-medication-therapy)
- [Telehealth (2)](https://blog.pocp.com/blog/tag/telehealth)
- [Telemedicine (2)](https://blog.pocp.com/blog/tag/telemedicine)
- [care coordination (2)](https://blog.pocp.com/blog/tag/care-coordination)
- [compliance (2)](https://blog.pocp.com/blog/tag/compliance)
- [ePA (2)](https://blog.pocp.com/blog/tag/epa)
- [eRx (2)](https://blog.pocp.com/blog/tag/erx)
- [health dashboards (2)](https://blog.pocp.com/blog/tag/health-dashboards)
- [medication management (2)](https://blog.pocp.com/blog/tag/medication-management)
- [opioid abuse (2)](https://blog.pocp.com/blog/tag/opioid-abuse)
- [patient access (2)](https://blog.pocp.com/blog/tag/patient-access)
- [pharmacist (2)](https://blog.pocp.com/blog/tag/pharmacist)
- [pharmacy business model (2)](https://blog.pocp.com/blog/tag/pharmacy-business-model)
- [prior authorizations (2)](https://blog.pocp.com/blog/tag/prior-authorizations)
- [wearables (2)](https://blog.pocp.com/blog/tag/wearables)
- [ACO (1)](https://blog.pocp.com/blog/tag/aco)
- [AI Policy (1)](https://blog.pocp.com/blog/tag/ai-policy)
- [Antikickback Statutes Reform (1)](https://blog.pocp.com/blog/tag/antikickback-statutes-reform)
- [Biologics and Biosimilars Naming (1)](https://blog.pocp.com/blog/tag/biologics-and-biosimilars-naming)
- [Biosimilars (1)](https://blog.pocp.com/blog/tag/biosimilars)
- [Business Process (1)](https://blog.pocp.com/blog/tag/business-process)
- [CAQH Phase V Operating Rules (1)](https://blog.pocp.com/blog/tag/caqh-phase-v-operating-rules)
- [CARIN Alliance (1)](https://blog.pocp.com/blog/tag/carin-alliance)
- [CDS Hooks (1)](https://blog.pocp.com/blog/tag/cds-hooks)
- [CMS Attachments Rule (1)](https://blog.pocp.com/blog/tag/cms-attachments-rule)
- [CMS-0062P (1)](https://blog.pocp.com/blog/tag/cms-0062p)
- [CRD (1)](https://blog.pocp.com/blog/tag/crd)
- [Canada Biosimilars Naming (1)](https://blog.pocp.com/blog/tag/canada-biosimilars-naming)
- [Canadian ePrescribing (1)](https://blog.pocp.com/blog/tag/canadian-eprescribing)
- [Chronic Disease (1)](https://blog.pocp.com/blog/tag/chronic-disease)
- [Clinical Quality Language (CQL) (1)](https://blog.pocp.com/blog/tag/clinical-quality-language-cql)
- [CodeX (1)](https://blog.pocp.com/blog/tag/codex)
- [CoverMyMeds (1)](https://blog.pocp.com/blog/tag/covermymeds)
- [DSMO (1)](https://blog.pocp.com/blog/tag/dsmo)
- [DTR (1)](https://blog.pocp.com/blog/tag/dtr)
- [DTx (1)](https://blog.pocp.com/blog/tag/dtx)
- [Data Modernization Initiative (1)](https://blog.pocp.com/blog/tag/data-modernization-initiative)
- [Data quality (1)](https://blog.pocp.com/blog/tag/data-quality)
- [Designated Standards Maintenance Organizations (1)](https://blog.pocp.com/blog/tag/designated-standards-maintenance-organizations)
- [Digital Therapeutics Opportunities (1)](https://blog.pocp.com/blog/tag/digital-therapeutics-opportunities)
- [Digital Therapeutics Outlook (1)](https://blog.pocp.com/blog/tag/digital-therapeutics-outlook)
- [Discover Alliance (1)](https://blog.pocp.com/blog/tag/discover-alliance)
- [Drug Launch (1)](https://blog.pocp.com/blog/tag/drug-launch)
- [Drug Manufacturers (1)](https://blog.pocp.com/blog/tag/drug-manufacturers)
- [Drug PA (1)](https://blog.pocp.com/blog/tag/drug-pa)
- [Drug abuse (1)](https://blog.pocp.com/blog/tag/drug-abuse)
- [EHR Apps (1)](https://blog.pocp.com/blog/tag/ehr-apps)
- [Enforcement (1)](https://blog.pocp.com/blog/tag/enforcement)
- [FDA (1)](https://blog.pocp.com/blog/tag/fda)
- [FQHC (1)](https://blog.pocp.com/blog/tag/fqhc)
- [Federally Qualified Health Centers (1)](https://blog.pocp.com/blog/tag/federally-qualified-health-centers)
- [Fee-for-service (1)](https://blog.pocp.com/blog/tag/fee-for-service)
- [Gold-carding (1)](https://blog.pocp.com/blog/tag/gold-carding)
- [HIN (1)](https://blog.pocp.com/blog/tag/hin)
- [HIPAA (1)](https://blog.pocp.com/blog/tag/hipaa)
- [HIT Leaders (1)](https://blog.pocp.com/blog/tag/hit-leaders)
- [HTI-4 (1)](https://blog.pocp.com/blog/tag/hti-4)
- [Health and Human Services (1)](https://blog.pocp.com/blog/tag/health-and-human-services)
- [Health data (1)](https://blog.pocp.com/blog/tag/health-data)
- [Health system (1)](https://blog.pocp.com/blog/tag/health-system)
- [Healthcare artificial intelligence trends (1)](https://blog.pocp.com/blog/tag/healthcare-artificial-intelligence-trends)
- [Human Services (1)](https://blog.pocp.com/blog/tag/human-services)
- [Hypertension (1)](https://blog.pocp.com/blog/tag/hypertension)
- [I-STOP (1)](https://blog.pocp.com/blog/tag/i-stop)
- [Insurance (1)](https://blog.pocp.com/blog/tag/insurance)
- [Landscape analysis (1)](https://blog.pocp.com/blog/tag/landscape-analysis)
- [MACRA (1)](https://blog.pocp.com/blog/tag/macra)
- [MIPS (1)](https://blog.pocp.com/blog/tag/mips)
- [Market Intelligence (1)](https://blog.pocp.com/blog/tag/market-intelligence)
- [Market Research (1)](https://blog.pocp.com/blog/tag/market-research)
- [Medication Therapy Management (1)](https://blog.pocp.com/blog/tag/medication-therapy-management)
- [Modernizing Part D CMS-4180-P (1)](https://blog.pocp.com/blog/tag/modernizing-part-d-cms-4180-p)
- [NCPDP F&B (1)](https://blog.pocp.com/blog/tag/ncpdp-fb)
- [NCPDP SCRIPT 2017071 (1)](https://blog.pocp.com/blog/tag/ncpdp-script-2017071)
- [NCPDP Workgroups (1)](https://blog.pocp.com/blog/tag/ncpdp-workgroups)
- [NCQA (1)](https://blog.pocp.com/blog/tag/ncqa)
- [NPI (1)](https://blog.pocp.com/blog/tag/npi)
- [Objective Analysis (1)](https://blog.pocp.com/blog/tag/objective-analysis)
- [Outcomes (1)](https://blog.pocp.com/blog/tag/outcomes)
- [P2 FHIR Taskforce (1)](https://blog.pocp.com/blog/tag/p2-fhir-taskforce)
- [PAS (1)](https://blog.pocp.com/blog/tag/pas)
- [PBMs (1)](https://blog.pocp.com/blog/tag/pbms)
- [PIE (1)](https://blog.pocp.com/blog/tag/pie)
- [POCP News (1)](https://blog.pocp.com/blog/tag/pocp-news)
- [Pain Management (1)](https://blog.pocp.com/blog/tag/pain-management)
- [Pharmacogenomics (1)](https://blog.pocp.com/blog/tag/pharmacogenomics)
- [Population Health Management (1)](https://blog.pocp.com/blog/tag/population-health-management)
- [Prescribing Authority (1)](https://blog.pocp.com/blog/tag/prescribing-authority)
- [Prescribing signatures (1)](https://blog.pocp.com/blog/tag/prescribing-signatures)
- [Prescription Price Transparency (1)](https://blog.pocp.com/blog/tag/prescription-price-transparency)
- [Prescription affordability (1)](https://blog.pocp.com/blog/tag/prescription-affordability)
- [Prescription drug benefit (1)](https://blog.pocp.com/blog/tag/prescription-drug-benefit)
- [Prescription pricing (1)](https://blog.pocp.com/blog/tag/prescription-pricing)
- [Public Health (1)](https://blog.pocp.com/blog/tag/public-health)
- [Quality Measures (1)](https://blog.pocp.com/blog/tag/quality-measures)
- [Quality Reporting (1)](https://blog.pocp.com/blog/tag/quality-reporting)
- [RTBT (1)](https://blog.pocp.com/blog/tag/rtbt)
- [RTPB (1)](https://blog.pocp.com/blog/tag/rtpb)
- [Regulatory overhead (1)](https://blog.pocp.com/blog/tag/regulatory-overhead)
- [RelayHealth (1)](https://blog.pocp.com/blog/tag/relayhealth)
- [Rx renewal (1)](https://blog.pocp.com/blog/tag/rx-renewal)
- [RxBC (1)](https://blog.pocp.com/blog/tag/rxbc)
- [Sandbox (1)](https://blog.pocp.com/blog/tag/sandbox)
- [Social Determinants of Health (1)](https://blog.pocp.com/blog/tag/social-determinants-of-health)
- [Specialty Pharmacy Enrollment (1)](https://blog.pocp.com/blog/tag/specialty-pharmacy-enrollment)
- [Specialty medication (1)](https://blog.pocp.com/blog/tag/specialty-medication)
- [Stark Anti-Kickback Statute (1)](https://blog.pocp.com/blog/tag/stark-anti-kickback-statute)
- [Stark Law Reform (1)](https://blog.pocp.com/blog/tag/stark-law-reform)
- [State policy (1)](https://blog.pocp.com/blog/tag/state-policy)
- [Surescripts (1)](https://blog.pocp.com/blog/tag/surescripts)
- [Telecommunications (1)](https://blog.pocp.com/blog/tag/telecommunications)
- [Telehealth / Telemedicine (1)](https://blog.pocp.com/blog/tag/telehealth-telemedicine)
- [U.S. Senate Special Committee on Aging (1)](https://blog.pocp.com/blog/tag/u-s-senate-special-committee-on-aging)
- [Uncategorized (1)](https://blog.pocp.com/blog/tag/uncategorized)
- [Virtual Visits (1)](https://blog.pocp.com/blog/tag/virtual-visits)
- [Working from home (1)](https://blog.pocp.com/blog/tag/working-from-home)
- [X12 (1)](https://blog.pocp.com/blog/tag/x12)
- [blockchain (1)](https://blog.pocp.com/blog/tag/blockchain)
- [care gaps (1)](https://blog.pocp.com/blog/tag/care-gaps)
- [community pharmacy (1)](https://blog.pocp.com/blog/tag/community-pharmacy)
- [consumerism (1)](https://blog.pocp.com/blog/tag/consumerism)
- [data platforms (1)](https://blog.pocp.com/blog/tag/data-platforms)
- [digiceuticals (1)](https://blog.pocp.com/blog/tag/digiceuticals)
- [digital health platforms (1)](https://blog.pocp.com/blog/tag/digital-health-platforms)
- [eConsent (1)](https://blog.pocp.com/blog/tag/econsent)
- [eMedication Management (1)](https://blog.pocp.com/blog/tag/emedication-management)
- [healthcare (1)](https://blog.pocp.com/blog/tag/healthcare)
- [home health (1)](https://blog.pocp.com/blog/tag/home-health)
- [machine learning (1)](https://blog.pocp.com/blog/tag/machine-learning)
- [medical deserts (1)](https://blog.pocp.com/blog/tag/medical-deserts)
- [patient generated data (1)](https://blog.pocp.com/blog/tag/patient-generated-data)
- [payers (1)](https://blog.pocp.com/blog/tag/payers)
- [payment model (1)](https://blog.pocp.com/blog/tag/payment-model)
- [prescription drug monitoring programs (1)](https://blog.pocp.com/blog/tag/prescription-drug-monitoring-programs)
- [rural health (1)](https://blog.pocp.com/blog/tag/rural-health)
- [vive (1)](https://blog.pocp.com/blog/tag/vive)
See all
[](https://www.pocp.com)
©2026 Point-of-Care Partners | All Rights Reserved
- [](https://twitter.com/pocpHIT)
- [](http://www.linkedin.com/company/point-of-care-partners)
- [](https://www.pocp.com/pocp-blog/)
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"author" : {
"@type" : "Person",
"name" : "Kim Boyd",
"url" : "https://blog.pocp.com/blog/author/kim-boyd"
},
"dateModified" : "2024-08-22T17:17:59.631Z",
"datePublished" : "2024-08-22T17:17:59.000Z",
"headline" : "Why the Life Science Industry Should Care About the Proposed HTI-2 Rule",
"image" : [ "https://blog.pocp.com/hubfs/_HTI2%20Life%20Sciences.png" ],
"mainEntityOfPage" : {
"@id" : "https://blog.pocp.com/blog/why-the-life-science-industry-should-care-about-the-proposed-hti-2-rule",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://blog.pocp.com/hubfs/pocp-logo-2016.jpg"
},
"name" : "Point-of-Care Partners"
}
}
```